Immunology and targeted therapy in Castleman disease

References

• Castleman B, Towne VW. CASE records of the Massachusetts general hospital weekly clinicopathological exercises: case 40011. N Engl J Med. 1954 Jan 7;250(1):26–30. doi: 10.1056/NEJM195401072500107
   PubMedGoogle Scholar
• Castleman B, Iverson L, Menedez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956 Jul;9(4):822–830. doi: 10.1002/1097-0142(195607/08)9:4<822:AID-CNCR2820090430>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Flendrig JA. Benign giant lymphoma: clinicopathologic correlation study. In: Clark R Gumley R, editors. The year book of cancer. Chicago: Year Book Medical Publishers; 1970. p. 296–299.
   Google Scholar
• Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972 Mar;29(3):670–683. doi: 10.1002/1097-0142(197203)
   PubMed Web of Science ®Google Scholar
• Mori S, Mohri N, Uchida T, et al. Idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia: a syndrome related to giant lymph node hyperplasia of plasma cell type]. J Jpn Soc Res (New York). 1980;20(suppl):55–65. [in Japanese].
   Google Scholar
• Frizzera G, Banks PM, Massarelli G, et al. A systemic lymphoproliferative disorder with morphologic features of Castlemanʼs disease. Am J Surg Pathol. 1983 Apr;7(3):211–232. doi: 10.1097/00000478-198304000-00001
   PubMed Web of Science ®Google Scholar
• Chen KT. Multicentric Castlemanʼs disease and Kaposiʼs sarcoma. Am J Surg Pathol. 1984 Apr;8(4):287–294. doi: 10.1097/00000478-198404000-00006
   PubMed Web of Science ®Google Scholar
• Lachant NA, Sun NC, Leong LA, et al. Multicentric angiofollicular lymph node hyperplasia (Castleman’s disease) followed by Kaposi’s sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol. 1985 Jan;83(1):27–33. doi: 10.1093/ajcp/83.1.27
   PubMed Web of Science ®Google Scholar
• Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995 Aug 15;86(4):1276–1280. doi: 10.1182/blood.V86.4.1276.bloodjournal8641276
   PubMed Web of Science ®Google Scholar
• Kishimoto T. Factors affecting B-cell growth and differentiation. Annu Rev Immunol. 1985;3:133–157. doi: 10.1146/annurev.iy.03.040185.001025
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood. 1989 Jul;74(1):1–10. doi: 10.1182/blood.V74.1.1.1
   PubMed Web of Science ®Google Scholar
• Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 1989 Sep;74(4):1360–1367. doi: 10.1182/blood.V74.4.1360.1360
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000 Jan 1;95(1):56–61. doi: 10.1182/blood.V95.1.56
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–2632. doi: 10.1182/blood-2004-12-4602
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020 Apr 16;135(16):1353–1364. doi: 10.1182/blood.2019000931
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 Mar 23;129(12):1646–1657. doi: 10.1182/blood-2016-10-746933
   PubMed Web of Science ®Google Scholar
• van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 Nov 15;132(20):2115–2124. doi: 10.1182/blood-2018-07-862334
   PubMed Web of Science ®Google Scholar
• van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020 Dec 8;4(23):6039–6050. doi: 10.1182/bloodadvances.2020003334
   PubMed Web of Science ®Google Scholar
• Takai K, Nikkuni K, Shibuya H, et al. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly Rinsho Ketsueki. [Rinsho Ketsueki] Jpn J Clin hematol. 2010;51(5):320–325. [in Japanese].
   PubMedGoogle Scholar
• Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016 Feb;91(2):220–226. doi: 10.1002/ajh.24242
   PubMed Web of Science ®Google Scholar
• Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53(1):57–61. doi: 10.3960/jslrt.53.57
   PubMedGoogle Scholar
• Takatsuki K, Sanada I. Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol. 1983 Sep;13(3):543–555.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology. 1984 Jun;34(6):712–720. doi: 10.1212/wnl.34.6.712
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014 May 8;123(19):2924–2933. doi: 10.1182/blood-2013-12-545087
   PubMed Web of Science ®Google Scholar
• Takeuchi K. Idiopathic plasmacytic lymphadenopathy: a conceptual history along with a translation of the original Japanese article published in 1980. J Clin Exp Hematop. 2022;62(2):79–84. doi: 10.3960/jslrt.22011
   PubMed Web of Science ®Google Scholar
• Gao YH, Liu YT, Zhang MY, et al. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. Br J Haematol. 2024 Feb 15;204(5):1830–1837. doi: 10.1111/bjh.19334
   PubMedGoogle Scholar
• Kojima M, Nakamura N, Tsukamoto N, et al. Clinical implications of idiopathic multicentric Castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol. 2008 Oct;16(4):391–398. doi: 10.1177/1066896908315812
   PubMed Web of Science ®Google Scholar
• Masaki Y, Kawabata H, Takai K, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020 Jan;111(1):155–158. doi: 10.1007/s12185-019-02780-1
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Nishimura MF, Sato Y. International definition of iMCD-TAFRO: future perspectives. J Clin Exp Hematop. 2022 Jun 28;62(2):73–78. doi: 10.3960/jslrt.21037
   PubMed Web of Science ®Google Scholar
• Nishimura MF, Nishimura Y, Nishikori A, et al. Historical and pathological overview of Castleman disease. J Clin Exp Hematop. 2022 Jun 28;62(2):60–72. doi: 10.3960/jslrt.21036
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Fajgenbaum DC, Pierson SK, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021 Oct 1;96(10):1241–1252. doi: 10.1002/ajh.26292
   PubMed Web of Science ®Google Scholar
• Szalat R, Munshi NC. Diagnosis of Castleman Disease. Hematol Oncol Clin North Am. 2018 Feb;32(1):53–64. doi: 10.1016/j.hoc.2017.09.005
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, Wu D, Goodman A, et al. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. 2020 Dec;95(12):1553–1561. doi: 10.1002/ajh.25992
   PubMed Web of Science ®Google Scholar
• Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009 Jul;16(4):236–246. doi: 10.1097/PAP.0b013e3181a9d4d3
   PubMed Web of Science ®Google Scholar
• Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000 Feb 15;95(4):1406–1412. doi: 10.1182/blood.V95.4.1406.004k26_1406_1412
   PubMed Web of Science ®Google Scholar
• Lazzi S, Bellan C, Amato T, et al. Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 infection in reactive lymphoid tissues: a model for KSHV/HHV-8-related lymphomas?. Hum Pathol. 2006 Jan;37(1):23–31. doi: 10.1016/j.humpath.2005.08.020
   PubMed Web of Science ®Google Scholar
• Nishikori A, Nishimura MF, Nishimura Y, et al. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease. Int J Mol Sci. 2022 Sep 7;23(18):10301. doi: 10.3390/ijms231810301
   PubMed Web of Science ®Google Scholar
• Fujiki T, Hirasawa S, Watanabe S, et al. Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome. CEN Case Rep. 2017 May;6(1):105–110. doi: 10.1007/s13730-017-0253-6
   PubMed Web of Science ®Google Scholar
• Carbone A, Pantanowitz L. TAFRO syndrome: an atypical variant of KSHV-negative multicentric Castleman disease. Am J Hematol. 2016 Feb;91(2):171–172. doi: 10.1002/ajh.24274
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, Shilling D. Castleman Disease Pathogenesis. Hematol Oncol Clin North Am. 2018 Feb;32(1):11–21. doi: 10.1016/j.hoc.2017.09.002
   PubMed Web of Science ®Google Scholar
• Vermi W, Lonardi S, Bosisio D, et al. Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol. 2008 Nov;216(3):356–364. doi: 10.1002/path.2420
   PubMed Web of Science ®Google Scholar
• Wong RSM. unicentric castleman disease. Hematol Oncol Clin North Am. 2018 Feb;32(1):65–73. doi: 10.1016/j.hoc.2017.09.006
   PubMed Web of Science ®Google Scholar
• Katano H, Sato Y, Kurata T, et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi’s sarcoma, and multicentric Castleman’s disease. Virology. 2000 Apr 10;269(2):335–344. doi: 10.1006/viro.2000.0196
   PubMed Web of Science ®Google Scholar
• Burger R, Neipel F, Fleckenstein B, et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood. 1998 Mar 15;91(6):1858–1863. doi: 10.1182/blood.V91.6.1858
   PubMed Web of Science ®Google Scholar
• Dispenzieri A. POEMS Syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019 Jul;94(7):812–827. doi: 10.1002/ajh.25495
   PubMed Web of Science ®Google Scholar
• Watanabe O, Arimura K, Kitajima I, et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet. 1996 Mar 9;347(9002):702. doi: 10.1016/s0140-6736(96)91261-1
   PubMed Web of Science ®Google Scholar
• Kawajiri-Manako C, Mimura N, Fukuyo M, et al. Clonal immunoglobulin λ light-chain gene rearrangements detected by next generation sequencing in POEMS syndrome. Am J Hematol. 2018 Sep;93(9):1161–1168. doi: 10.1002/ajh.25213
   PubMed Web of Science ®Google Scholar
• D’Souza A, Hayman SR, Buadi F, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011 Oct 27;118(17):4663–4665. doi: 10.1182/blood-2011-06-362392
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Kawabata H, Sakai T, et al. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol. 2021 Jan;113(1):73–80. doi: 10.1007/s12185-020-03008-3
   PubMed Web of Science ®Google Scholar
• Sarmiento Bustamante M, Shyamsundar S, Coren FR, et al. Ongoing symptoms following complete surgical excision in unicentric Castleman disease. Am J Hematol. 2023 Nov;98(11):E334–E337. doi: 10.1002/ajh.27065
   PubMed Web of Science ®Google Scholar
• Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1–78. doi: 10.1016/s0065-2776(08)60532-5
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect Biol. 2018 Aug 1;10(8):a028456. doi: 10.1101/cshperspect.a028456
   PubMed Web of Science ®Google Scholar
• Choy EH, De Benedetti F, Takeuchi T, et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020 Jun;16(6):335–345. doi: 10.1038/s41584-020-0419-z
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992 Oct 23;258(5082):593–597. doi: 10.1126/science.1411569
   PubMed Web of Science ®Google Scholar
• Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990 Dec 21;63(6):1149–1157. doi: 10.1016/0092-8674(90)90411-7
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003 Aug 15;374(Pt 1):1–20. doi: 10.1042/BJ20030407
   PubMedGoogle Scholar
• Yoshizaki K, Murayama S, Ito H, et al. The Role of Interleukin-6 in Castleman Disease. Hematol Oncol Clin North Am. 2018 Feb;32(1):23–36. doi: 10.1016/j.hoc.2017.09.003
   PubMed Web of Science ®Google Scholar
• van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–974. doi: 10.1016/S1470-2045(14)70319-5 Erratum in: Lancet Oncol. 2014;15(10):417.
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007 Sep;44(16):3823–3837. doi: 10.1016/j.molimm.2007.06.151
   PubMed Web of Science ®Google Scholar
• Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001 Dec 1;98(12):3473–3475. doi: 10.1182/blood.v98.12.3473
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014 Dec 4;124(24):3544–3552. doi: 10.1182/blood-2014-07-586800
   PubMed Web of Science ®Google Scholar
• Ide M, Kawachi Y, Izumi Y, et al. Long-term remission in HIV-negative patients with multicentric Castleman’s disease using rituximab. Eur J Haematol. 2006 Feb;76(2):119–123. doi: 10.1111/j.1600-0609.2005.00570.x
   PubMed Web of Science ®Google Scholar
• Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med. 2000 Jun 21;2(4):1–23. doi: 10.1017/S1462399400001769
   PubMedGoogle Scholar
• Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008 Sep;14(9):931–938. doi: 10.1038/nm.1857
   PubMed Web of Science ®Google Scholar
• Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008 Oct;19(10):2001–2010. doi: 10.1681/ASN.2007121272
   PubMed Web of Science ®Google Scholar
• Yamaga Y, Tokuyama K, Kato T, et al. Successful treatment with Cyclosporin a in tocilizumab-resistant TAFRO syndrome. Intern Med. 2016;55(2):185–190. doi: 10.2169/internalmedicine.55.4710
   PubMed Web of Science ®Google Scholar
• Shirai T, Onishi A, Waki D, et al. Successful treatment with tacrolimus in TAFRO syndrome: two case reports and literature review. Medicine (Baltimore). 2018 Jun;97(23):e11045. doi: 10.1097/MD.0000000000011045
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, Langan RA, Japp AS, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019 Aug 13;129(10):4451–4463. doi: 10.1172/JCI126091
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003 May;35(3):S7–S14. doi: 10.1016/s0041-1345(03)00211-2
   PubMed Web of Science ®Google Scholar
• Teachey DT, Obzut DA, Axsom K, et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. 2006 15;108(6):1965–1971. doi: 10.1182/blood-2006-01-010124
   PubMed Web of Science ®Google Scholar
• McCarthy C, Gupta N, Johnson SR, et al. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med. 2021 Nov;9(11):1313–1327. doi: 10.1016/S2213-2600(21)00228-9
   PubMed Web of Science ®Google Scholar
• Sumiyoshi R, Koga T, Furukawa K, et al. A case of tocilizumab-refractory idiopathic multicentric Castleman’s disease successfully treated with sirolimus. Clin Immunol. 2021 Dec;233:108887. doi: 10.1016/j.clim.2021.108887
   PubMed Web of Science ®Google Scholar
• Koga T, Takemori S, Hagimori N, et al. An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant). Medicine (Baltimore). 2020 Dec 11;99(50):e23291. doi: 10.1097/MD.0000000000023291
   PubMed Web of Science ®Google Scholar
• Arenas DJ, Floess K, Kobrin D, et al. Increased mTOR activation in idiopathic multicentric Castleman disease. Blood. 2020 May 7;135(19):1673–1684. doi: 10.1182/blood.2019002792
   PubMed Web of Science ®Google Scholar
• Phillips AD, Kakkis JJ, Tsao PY, et al. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO. J Cell Mol Med. 2022;26(11):3147–3152. doi: 10.1111/jcmm.17251
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB, Hu X. Signaling by STATs. Arthritis Res Ther. 2004;6(4):159–168. doi: 10.1186/ar1197
   PubMed Web of Science ®Google Scholar
• Kang S, Tanaka T, Narazaki M, et al. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019 Apr 16;50(4):1007–1023. doi: 10.1016/j.immuni.2019.03.026
   PubMed Web of Science ®Google Scholar
• Pierson SK, Shenoy S, Oromendia AB, et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021;5(17):3445–3456. doi: 10.1182/bloodadvances.2020004016
   PubMed Web of Science ®Google Scholar
• Killian M, Viel S, Chalayer E, et al. JAK1/2 Inhibition in Severe TAFRO Syndrome: A Case Report. Ann Intern Med. 2021 May;174(5):719–721. doi: 10.7326/L20-1051
   PubMed Web of Science ®Google Scholar
• Lust H, Gong S, Remiker A, et al. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series. Pediatr Blood Cancer. 2021;68(10):e29261. doi: 10.1002/pbc.29261
   PubMed Web of Science ®Google Scholar
• Pierson SK, Stonestrom AJ, Shilling D, et al. Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease. Am J Hematol. 2018 Jul;93(7):902–912. doi: 10.1002/ajh.25123
   PubMed Web of Science ®Google Scholar
• Pierson SK, Katz L, Williams R, et al. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nat Commun. 2022 Nov 24;13(1):7236. doi: 10.1038/s41467-022-34873-7
   PubMed Web of Science ®Google Scholar
• Havenar-Daughton C, Lindqvist M, Heit A, et al. CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci USA 2016 Mar 8;113(10):2702–2707. doi: 10.1073/pnas.1520112113
   PubMed Web of Science ®Google Scholar
• Rao DA. T cells that help B cells in chronically inflamed tissues. Front Immunol. 1924 2018 Aug 23;9. doi: 10.3389/fimmu.2018.01924
   Google Scholar
• Nakayama S, Taguchi N, Isaka Y, et al. Glibenclamide and Therapeutic Hypothermia Have Comparable Effect on Attenuating Global Cerebral Edema Following Experimental Cardiac Arrest. Neurocrit Care. 2018 Aug;29(1):119–127. doi: 10.1007/s12028-017-0479-3
   PubMed Web of Science ®Google Scholar
• Yoshitomi H, Ueno H. Shared and distinct roles of T peripheral helper and T follicular helper cells in human diseases. Cell Mol Immunol. 2021 Mar;18(3):523–527. doi: 10.1038/s41423-020-00529-z
   PubMed Web of Science ®Google Scholar
• Bocharnikov AV, Keegan J, Wacleche VS, et al. Accelerating Medicines Partnership (AMP) RA/SLE Network. PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight. 2019 Oct 17;4(20):e130062. doi: 10.1172/jci.insight.130062
   PubMedGoogle Scholar
• Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011 Aug 16;20(2):246–259. doi: 10.1016/j.ccr.2011.06.029
   PubMed Web of Science ®Google Scholar
• Harada T, Kikushige Y, Miyamoto T, et al. Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease. Nat Commun. 2023 Oct 31;14(1):6959. doi: 10.1038/s41467-023-42718-0
   PubMed Web of Science ®Google Scholar
• Iwaki N, Gion Y, Kondo E, et al. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep. 2017 Feb 13;7:42316. doi: 10.1038/srep42316
   PubMed Web of Science ®Google Scholar
• Yuan ZG, Dun XY, Li YH, et al. Treatment of multicentric Castleman’s Disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol. 2009 Apr 28;2:19. doi: 10.1186/1756-8722-2-19
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang MY, Cao XX, et al. A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. Leuk Lymphoma. 2022 Mar;63(3):618–626. doi: 10.1080/10428194.2021.1999437
   PubMed Web of Science ®Google Scholar
• Sato K, Tsuchiya M, Saldanha J, et al. Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol Immunol. 1994 Apr;31(5):371–381. doi: 10.1016/0161-5890(94)90115-5
   PubMed Web of Science ®Google Scholar